2020
DOI: 10.6026/97320630016387
|View full text |Cite
|
Sign up to set email alerts
|

Molecular Docking analysis of the TNIK Receptor protein with a potential Inhibitor from the NPACT database

Abstract: It is of interest to design and develop efficient inhibitors to the TNIK protein target in Wnt signaling pathways in the context of colorectal cancer (CRC) using molecular docking models. We show data to support that a compound named aglafoline (methyl (1R,2R,3S,3aR,8bS)-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H cyclopenta [b] [1] from the NPACT (Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database) database have optimal binding features with the TNIK r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…We also performed molecular docking of the free ligand and the five metal complexes with colon and breast cancer–related proteins. For colon cancer, we selected TNIK (PDB = 2X7F) and topoisomerase II enzyme (PDB = 4F9M), which are candidate therapeutic targets for colorectal cancer ( Sapna Rani and Kumar, 2014 ; Lee et al, 2017 ; Rosita and Begum, 2020 ). Moreover, the breast cancer–associated estrogen receptor (ID: 3ERT) and Hsp90 protein receptor (ID: 1H7K) were chosen based on previous research suggesting their value as targets for potential breast cancer therapy ( Zagouri et al, 2013 ; Acharya et al, 2019 ).…”
Section: Resultsmentioning
confidence: 99%
“…We also performed molecular docking of the free ligand and the five metal complexes with colon and breast cancer–related proteins. For colon cancer, we selected TNIK (PDB = 2X7F) and topoisomerase II enzyme (PDB = 4F9M), which are candidate therapeutic targets for colorectal cancer ( Sapna Rani and Kumar, 2014 ; Lee et al, 2017 ; Rosita and Begum, 2020 ). Moreover, the breast cancer–associated estrogen receptor (ID: 3ERT) and Hsp90 protein receptor (ID: 1H7K) were chosen based on previous research suggesting their value as targets for potential breast cancer therapy ( Zagouri et al, 2013 ; Acharya et al, 2019 ).…”
Section: Resultsmentioning
confidence: 99%